Arca
Skip to content

NORTHERA (droxidopa): Complete Response Letter

A complete response letter is FDA's decision not to approve an application as submitted. See NDA 203202's history or Chelsea Therapeutics, Inc.'s company page.

On Mar 28, 2012, FDA declined to approve NORTHERA (droxidopa) (NDA 203202) from Chelsea Therapeutics, Inc. in its present form, citing clinical/ statistical, labeling, risk evaluation and mitigation strategy requirements. The application was later approved.

  • Letter date: Mar 28, 2012
  • Application: NDA 203202
  • Since then: Approved

What FDA Cited

FDA's own section headings in the letter; each finds other letters citing it

Clinical/ statisticalLabelingRisk evaluation and mitigation strategy requirementsProduct qualityClinical pharmacology

The Letter

Text from openFDA

You submitted the results of 3 clinical trials (studies 301, 302, and 303) to support the efficacy of droxidopa for the treatment of neurogenic orthostatic hypotension (NOH). Study 302 was conducted first and was a negative study, based on the primary endpoint...… openFDA did not return the full text just now. Open it in the letter search.

Record

Company
Chelsea Therapeutics, Inc.
Application
NDA 203202
Status in openFDA
Approved
Review division
Office of Drug Evaluation I

FDA has published complete response letters since 2025, with some redactions. The status is openFDA's: whether the application was eventually approved. openFDA complete response letters

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.